GRCE

Grace Therapeutics, Inc.

GRCE.US gracetx.com + Research + Basket
CIK 0001444192
Employees 5
Phone 609 322 1602
Fiscal year end March
IPO Oct 08, 2024
Address 103 Carnegie Center, Princeton, NJ, United States, 08540
1.87
+0.06 (+3.31%)
USD · NASDAQ
52-week range
1.67
5.18
Trading at 6% of the 52-week range
Market Cap
39.34M
P/E Ratio
0.00
Forward P/E
2.17
Book Value
2.96
Div. Yield
N/A
% Institutions
31.60%
% Insiders
18.68%

1 Year

-40.6%

3 Year

-22.1%

10 Year

-97.1%
Description

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Actions

Add an action for GRCE.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Prashant Kohli CEO & Director 1972
Mr. Amresh Kumar Ph.D. VP of Program Management 1980
Ms. Carrie D'Andrea Consultant 1973
Mr. Robert J. DelAversano CPA VP of Finance and Principal Financial & Accounting Officer 1972
Dr. R. Loch MacDonald M.D., Ph.D. Member of Scientific Advisory Board & Chief Medical Officer 1962

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HPM Partners LLC 849.06K Jun 30, 2026 5.22% $0.00 0.00%
Eversept Partners, LP 772.90K Jun 30, 2026 4.75% $0.09 2.15%
Bank of America Corp 494.70K Jun 30, 2026 3.04% $0.00 -0.01%
Vanguard Capital Management, LLC 411.71K Jun 30, 2026 2.53% $0.00 2.50%
Citadel Advisors Llc 349.74K Jun 30, 2026 2.15% $0.00 254.20%
CANTOR FITZGERALD, L. P. 200.00K Jun 30, 2026 1.23% $0.00 0.00%
MAVEN SECURITIES Ltd 200.00K Jun 30, 2026 1.23% $0.01 0.00%
Birchview Capital, LP 120.00K Jun 30, 2026 0.74% $0.13 140.00%
Two Sigma Investments LLC 96.89K Jun 30, 2026 0.60% $0.00 0.00%
Jane Street Group LLC 89.44K Jun 30, 2026 0.55% $0.00 -46.47%
XTX Topco Ltd 71.67K Jun 30, 2026 0.44% $0.00 13.59%
HRT FINANCIAL LLC 62.69K Jun 30, 2026 0.39% $0.00 0.00%
Susquehanna International Group, LLP 49.58K Jun 30, 2026 0.30% $0.00 0.00%
BlackRock Inc 37.54K Jun 30, 2026 0.23% $0.00 0.00%
KESTRA PRIVATE WEALTH SERVICES, LLC 23.00K Jun 30, 2026 0.14% $0.00 76.92%
UBS Group AG 16.78K Jun 30, 2026 0.10% $0.00 -36.21%
Fundamentun, LLC 11.16K Jun 30, 2026 0.07% $0.00 0.00%
BNP Paribas Arbitrage, SA 10.50K Jun 30, 2026 0.06% $0.00 47.89%
Scientech Research LLC 10.18K Jun 30, 2026 0.06% $0.02 0.00%
Virtu Financial LLC 10.17K Jun 30, 2026 0.06% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 400.35K 2.46% ▲ 0.00% Sep 30, 2026
2 iShares Micro-Cap ETF 33.57K 0.21% ▼ 0.69% Sep 30, 2026
3 Fidelity Nasdaq Composite Index 3.21K 0.02% ▲ 0.00% Aug 31, 2026
4 1290 VT Micro Cap K 2.35K 0.01% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $39.34M
EBITDA: $-10.36M
Book Value: $2.96
Earnings/Share: $-1.21
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -10.81%
ROE (TTM): -36.19%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $24.11M
Trailing P/E: 0.00
Forward P/E: 2.17

Shares Statistics

Shares Outstanding: 21.04M
Shares Float: 13.38M
% Insiders: 18.68%
% Institutions: 31.60%
Short % Float: 9.45%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-7.00K
Gross Profit
subtotal
$-7.00K
SG&A
adjust
$-8.67M
R&D
adjust
$-2.41M
Other Operating Expense
adjust
$-7.00K
Operating Income
subtotal
$-11.08M
Other / Non-Operating Items
adjust
$3.28M
Net Income
subtotal
$-7.79M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GRCE.US!